CVS Health (CVS) Model Not Broken, Buy on Weakness - Guggenheim
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Guggenheim analyst John Heinbockel said at flat 2017 at CVS Health (NYSE: CVS) doesn't mean the model is broken. He said patient, value investors should find the shares compelling..
Heinbocke commented, "With the shares off 15% pre-market (vs. 2% decline in the S&P), a significant move for a $90B market cap company, after already declining 15% YTD (vs. 4% rise in the S&P), the market is acting as if the operating model is broken. It is a bit reminiscent of late 2009, when the shares took a substantial hit on ongoing choppy results at Caremark. We do not believe that the model—operating multiple Rx assets and touch points under one roof to drive better health outcomes and market share—is broken. At a 12x P/E on 2017 guidance, it is now cheaper than many slower-growing, less well-positioned businesses. We would be Buyers on this weakness."
The firm had a Buy rating and price target of $115 on CVS into the results.
Shares of CVS Health closed at $83.39 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Cuts Price Target on Workday (WDAY) to $71 Following 3Q
- BTIG Cuts PT on Workday (WDAY) to $88 Following Q3 Results; Affirms at 'Buy'
- Jefferies Cuts Price Target on PG&E Corp. (PCG) to $65 Following Rate Case Decision
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View
Related EntitiesStandard & Poor's, Guggenheim
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!